Investment Objective
Emkay Capital Builder AIF is an open-ended Multi-cap Category 3 AIF, that aims to identify companies with the potential to build wealth over an investment horizon of 3-5+ years.
The fund considers top 600 companies (by market cap) as its universe and is guided by a well-defined portfolio construction discipline to filter stocks based on strict limits and a three-pronged investment process.
Three-Pronged Investment Process
Earnings Growth
E-Qual Risk Framework
Purchase Price Discipline
Investment Framework
Long Term Investing
- Low churn
- Be patient before & after investing
Conviction & Patience
- Focus on absolute Returns and high emphasis on Purchase Price.
Compounding is the Name of the Game
- Winning sustainable wealth.
Do your own Homework
- Research backed & process oriented investments.
Focused Portfolio
- Allocation Discipline to avoid concentration risk.
Avoid Mistakes
- Avoid unscrupulous promoters/ management
- Businesses getting irrelevant
- Highly leveraged companies
- Euphoric valuation
Investment Theme
Using a bottom-up stock-picking strategy, the Capital Builder AIF aims to consistently identify businesses offering robust growth prospects and intrinsic value at a reasonable price. We employ in-house tools like E-Qual (India’s first governance-dedicated stock-picking model) to mitigate risks related to management quality.
Sector Allocation
Emkay Capital Builder uses a multi-cap strategy with 20-25 stocks.
*As on 31st March 2022
The underlying portfolio strategy for the Capital builder AIF has been a consistent performing with zero blowouts since its inception. This can largely be attributed to the intensive processes laid out in the E-Qual Risk module that make it nearly impossible for any evasive business to make its way into the fund.
TOP 5 HOLDINGS | PERCENTAGE |
---|---|
DIVI S LABORATORIES LTD | 12.5% |
ZOMATO LTD | 11.3% |
ICICI BANK LTD | 10.0% |
HDFC BANK LTD | 9.3% |
SUN PHARMACEUTICAL INDUSTRIES LTD | 8.2% |
TOP 5 HOLDINGS | |
---|---|
DIVI S LABORATORIES LTD | 10.8% |
ICICI BANK LTD. | 10.3% |
ZOMATO LIMITED | 9.9% |
HDFC Bank Ltd | 9.3% |
SUN PHARMACEUTICAL INDUSTRIES LTD | 7.7% |
Performance Update (Emkay Capital Builder PMS)
*As on 31st March 2022
Name | Since Inception |
---|---|
Emkay Capital Builder TWRR | 20.50 |
BSE 500 (TRI) | 12.50 |
Outperformance (TWRR v/s Benchmark) | 8.00 |
Note: The portfolio returns are TWRR returns.
*As on 31st March 2022
Get the Emkay Capital Builder Presentation On Your Mail
Get the Emkay Capital Builder Presentation On Your Mail
SEBI Registration Details
Entity Name | Type/ Nature of business Activity | SEBI Registration No. | Fund Managers |
---|---|---|---|
Emkay Emerging Stars Trust | SEBI Registered CAT III Alternative Investment Fund | IN/AIF3/24-25/1499 |
|
To know more about the Emkay Capital Builder portfolio and to receive the latest market outlook and guidance, talk to an Investment Adviser at EIML.
Long Term Investing
- Low churn
- Be patient before & after investing
Conviction & Patience
Focus on absolute Returns and high emphasis on Purchase Price.
Compounding is the Name of the Game
Winning sustainable wealth.
Do your own Homework
Research backed & process oriented investments.
Focused Portfolio
Allocation Discipline to avoid concentration risk.
Avoid Mistakes
- Avoid unscrupulous promoters/ management
- Businesses getting irrelevant
- Highly leveraged companies
- Euphoric valuation
TOP 5 HOLDINGS | |
---|---|
DIVI S LABORATORIES LTD | 10.80% |
ICICI BANK LTD. | 10.30% |
ZOMATO LIMITED | 9.90% |
HDFC Bank Ltd | 9.30% |
SUN PHARMACEUTICAL INDUSTRIES LTD | 7.70% |
213 | |
TOP 5 HOLDINGS |